Advil Congestion Relief

Advil Congestion Relief Manufacturers

• Lil’ Drug Store Products, Inc
  

  ×

  Advil Congestion Relief | Lil' Drug Store Products, Inc

  

  ---

  do not take more than directed adults and children 12 years of age and over: take 1 tablet every 4 hours while symptoms persist do not use more than 6 tablets in any 24-hour period unless directed by a doctor children under 12 years of age: do not use because this product contains too much medication for children under this age

  Close
  No Recall

  More Info
• Pfizer Consumer Healthcare
  

  ×

  Advil Congestion Relief | Upsher-smith Laboratories, Inc.

  

  ---

  2.1 Congestive Heart Failure Post-Myocardial Infarction

  Treatment should be initiated at 25 mg once daily and titrated to the recommended dose of 50 mg once daily, preferably within 4 weeks as tolerated by the patient. Eplerenone tablets may be administered with or without food.

  Once treatment with eplerenone tablets has begun, adjust the dose based on the serum potassium level as shown in Table 1.

  Table 1: Dose Adjustment in Congestive Heart Failure Post-MI

  Serum

  Potassium

  (mEq/L)

  Action

  Dose Adjustment

  <5

  Increase

  25 mg every other day to 25 mg once daily

  25 mg once daily to 50 mg once daily

  5 to 5.4

  Maintain

  No adjustment

  5.5 to 5.9

  Decrease

  50 mg once daily to 25 mg once daily

  25 mg once daily to 25 mg every other day

  25 mg every other day to withhold

  ≥ 6

  Withhold

  Restart at 25 mg every other day when potassium levels fall to <5.5 mEq/L

  2.2 Hypertension

  The recommended starting dose of eplerenone tablets is 50 mg administered once daily. The full therapeutic effect of eplerenone tablets is apparent within 4 weeks. For patients with an inadequate blood pressure response to 50 mg once daily the dosage of eplerenone tablets should be increased to 50 mg twice daily. Higher dosages of eplerenone tablets are not recommended because they have no greater effect on blood pressure than 100 mg and are associated with an increased risk of hyperkalemia [see CLINICAL STUDIES (14.2)].

  2.3 Recommended Monitoring

  Serum potassium should be measured before initiating eplerenone tablet therapy, within the first week, and at one month after the start of treatment or dose adjustment. Serum potassium should be assessed periodically thereafter. Patient characteristics and serum potassium levels may indicate that additional monitoring is appropriate [see WARNINGS AND PRECAUTIONS (5.1), ADVERSE REACTIONS (6.2)]. In the EPHESUS study [see CLINICAL STUDIES (14.1)], the majority of hyperkalemia was observed within the first three months after randomization.

  In all patients taking eplerenone tablets who start taking a moderate CYP3A4 inhibitor, check serum potassium and serum creatinine in 3 to 7 days.

  2.4 Dose Modifications for Specific Populations

  For hypertensive patients receiving moderate CYP3A4 inhibitors (e.g., erythromycin, saquinavir, verapamil, and fluconazole), the starting dose of eplerenone tablets should be reduced to 25 mg once daily [see DRUG INTERACTIONS (7.1)].

  No adjustment of the starting dose is recommended for the elderly or for patients with mild-to-moderate hepatic impairment [see CLINICAL PHARMACOLOGY (12.3)].

  Close
  No Recall

  More Info